Private Advisor Group LLC Has $1.63 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Private Advisor Group LLC lowered its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,454 shares of the company’s stock after selling 6,279 shares during the period. Private Advisor Group LLC’s holdings in Moderna were worth $1,634,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Moderna by 42.9% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock worth $164,724,000 after acquiring an additional 463,960 shares during the period. Lake Street Private Wealth LLC acquired a new stake in Moderna during the 1st quarter worth $239,000. Norden Group LLC acquired a new stake in Moderna during the 1st quarter worth $1,337,000. Westside Investment Management Inc. acquired a new stake in Moderna during the 1st quarter worth $32,000. Finally, First Trust Direct Indexing L.P. grew its holdings in Moderna by 31.8% during the 1st quarter. First Trust Direct Indexing L.P. now owns 4,924 shares of the company’s stock worth $525,000 after acquiring an additional 1,188 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on MRNA shares. Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Barclays lowered their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $94.65.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock valued at $238,531 in the last three months. 15.70% of the stock is currently owned by corporate insiders.

Moderna Trading Down 0.9 %

MRNA opened at $54.72 on Thursday. The stock has a market capitalization of $20.97 billion, a P/E ratio of -3.52 and a beta of 1.66. Moderna, Inc. has a 12 month low of $52.26 and a 12 month high of $170.47. The firm’s fifty day simple moving average is $66.34 and its 200 day simple moving average is $102.02. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the firm posted ($3.62) EPS. The firm’s revenue was down 29.9% compared to the same quarter last year. As a group, research analysts anticipate that Moderna, Inc. will post -9.88 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.